COVID-19 Nucleocapsid Protein mRNA-LNP

Item Information
Catalog #
Size
Price
Description

The spike protein of COVID-19 is a glycoprotein that helps the virus attach to various surfaces in the built environment, increasing the potential for virus transmission. The best-known vaccines we use are the spike protein vaccines delivered via mRNA. While the role of vaccination in controlling outbreaks is undeniable, the recurring emergence of new variants of Covid-19, such as the Delta and Omicron variants, poses new challenges, particularly their rapid global spread. It is thought that the development of a COVID-19 nucleocapsid (N) protein vaccine may prevent the re-emergence of Covid-19 due to its new variants. The N protein is a protein that packages the positive-sense RNA genome of coronaviruses to form a ribonucleoprotein structure enclosed within the viral capsid. The N protein is the most highly expressed of the four major coronavirus structural proteins. In addition to interacting with RNA, N also forms protein-protein interactions with coronavirus membrane proteins during virus assembly. The N protein is highly immunogenic, and N antibodies were found in recovered COVID-19 patients. This product is designed as a tool for the delivery and expression of full-length nucleocapsid protein mRNA for vaccine research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of the COVID-19 nucleocapsid protein mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The nucleocapsid protein sequence consists of 419 amino acids, and GenPept accession number is YP_009724397. The full-length amino acid sequence of this Nucleocapsid mRNA-LNP product is available upon request.

Product Overview
Composition
mRNA-LNPs suspended in PBS (-Ca, -Mg) (pH: 7.0-7.4).
Cell Type Tested
HEK293S
Application & Handing
Upon receiving product, briefly pulse spin before opening to ensure product is at bottom of container. It is important not to spin for too long as this may rupture mRNA-LNPs. Do not vortex. Work with mRNA-LNPs on ice and minimize the time that the product spends at room temperature. After handling the product during experiments, return immediately to ice. mRNA-LNP products should only be handled with certified RNase-free reagents and consumables. Use of filtered pipette tips is highly recommended.
Storage
4°C; ice
Product Image
COVID-19 Nucleocapsid Protein Expression in HEK293s Cells
Figure 1: COVID-19 nucleocapsid protein expression in HEK293s cells transfected by PM-LNP-0013, checked by FACS 48 hours post transfection. Cells were stained by 1° ab: ProMab Anti-Sars-Cov2-NP3; 2° ab: Jackson ImmunoResearch R-Phycoerythrin AffiniPure F(ab’)2 Fragment Goat Anti-Mouse IgG. Transfected cells were gated by non-transfected HEK293s cells grown under identical conditions. Cell morphology may be affected by transfection.
Figure 1: COVID-19 nucleocapsid protein expression in HEK293s cells transfected by PM-LNP-0013, checked by FACS 48 hours post transfection. Cells were stained by 1° ab: ProMab Anti-Sars-Cov2-NP3; 2° ab: Jackson ImmunoResearch R-Phycoerythrin AffiniPure F(ab’)2 Fragment Goat Anti-Mouse IgG. Transfected cells were gated by non-transfected HEK293s cells grown under identical conditions. Cell morphology may be affected by transfection.
For Research Use Only. Not for use in diagnostic procedures.